NCT04930783 — NeoVax neoantigen vaccine trial
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
Registry record
| Registry ID | NCT04930783 ↗ |
|---|---|
| Lead sponsor | Dana-Farber Cancer Institute |
| Collaborators | Celldex Therapeutics |
| Phase | Phase 1 |
| Status | Active Not Recruiting |
| Indication | Melanoma, Metastatic Melanoma |
| Enrollment | 10 participants (target) |
| Start date | 2022-01-03 |
| Primary completion | 2027-12-31 (est.) |
| Last registry update | 25 Mar 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT04930783), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT04930783?
NCT04930783 (NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma) is registered on ClinicalTrials.gov as Phase 1, sponsored by Dana-Farber Cancer Institute.
Is NCT04930783 recruiting?
As of the 2026-03-25 registry update, NCT04930783 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT04930783?
The lead sponsor is Dana-Farber Cancer Institute. Collaborators: Celldex Therapeutics.
What condition does NCT04930783 study?
The registered conditions are Melanoma, Metastatic Melanoma. Primary completion is listed as 2027-12-31 (estimated).
Are results available for NCT04930783?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT04930783.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.